CVSI - CV Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

0.0480

+0.0030

(+6.67%)

At close: 03:58PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.0450
Open	0.0401
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.0401 - 0.0484
52 Week Range	0.0300 - 0.0700
Volume	162,637
Avg. Volume	151,044

Market Cap	7.301M
Beta (5Y Monthly)	1.02
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0100
Earnings Date	Aug 14, 2023 - Aug 18, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CVSI

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
CV Sciences to Participate in LD Micro Invitational Conference
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that Joseph Dowling, its Chief Executive Officer, will present at the LD Micro Invitational Conference in Los Angeles, California on June 7, 2023. This prominent investor conference showcases companies to micro-cap investors as they search for the next generation
PR Newswire
CV Sciences, Inc. Reports First Quarter 2023 Financial Results
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023.
PR Newswire
CV SCIENCES, INC. TO ANNOUNCE FIRST QUARTER 2023 RESULTS ON MAY 15, 2023
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2023, before the stock market opens on Monday, May 15, 2023. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that
PR Newswire
CV Sciences, Inc. Introduces New THC Offering
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Extra Gummies, the latest addition to the Company's popular +PlusCBD product line.
PR Newswire
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2022.
PR Newswire
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year and fourth quarter ended December 31, 2022, before the stock market opens on Wednesday, March 29, 2023. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m.
PR Newswire
CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced that recently the Company received its formal Certificate of Grant from the Japan Patent Office (JPO) for its patent application 7216697.
PR Newswire
CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced the launch of +PlusCBD™Daily Balance THC-Free Gummies and Softgels. These new additions to the +PlusCBD™ product portfolio are now available for purchase at +PlusCBD.
PR Newswire
CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD™ Reserve Collection Softgels
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced the launch of their popular +PlusCBD™ Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on Thursday, Jan. 19.
PR Newswire
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2022.
PR Newswire
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2022 RESULTS ON NOVEMBER 14, 2022
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2022, before the stock market opens on Monday, November 14, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.
PR Newswire
CV Sciences, Inc. Extinguishes Convertible Debt
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences extinguished its entire outstanding convertible debt.
PR Newswire
CV Sciences, Inc. Announces Launch of PlusCBD™ Reserve Collection Softgels
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed, natural ingredients and products, today announced the launch of +PlusCBD™Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022.
PR Newswire
CV Sciences, Inc. Reports Second Quarter 2022 Financial Results
CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2022.